Compare IBRX & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | KNX |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.0B |
| IPO Year | 2015 | 2010 |
| Metric | IBRX | KNX |
|---|---|---|
| Price | $7.59 | $57.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 18 |
| Target Price | $12.57 | ★ $61.39 |
| AVG Volume (30 Days) | ★ 24.1M | 2.7M |
| Earning Date | 05-11-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.30% |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | $113,288,000.00 | ★ $7,469,689,000.00 |
| Revenue This Year | $88.59 | $5.92 |
| Revenue Next Year | $131.15 | $7.91 |
| P/E Ratio | ★ N/A | $135.17 |
| Revenue Growth | ★ 668.31 | 0.80 |
| 52 Week Low | $1.83 | $36.69 |
| 52 Week High | $12.43 | $64.10 |
| Indicator | IBRX | KNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 54.65 |
| Support Level | $2.25 | $51.70 |
| Resistance Level | $8.28 | $59.89 |
| Average True Range (ATR) | 0.93 | 2.00 |
| MACD | -0.24 | 0.37 |
| Stochastic Oscillator | 39.00 | 95.69 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.